Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Lung Neoplasms 2 Disease 2 Colorectal Neoplasms 2 Acute Kidney Injury 2 Urinary Bladder Neoplasms 1 Tuberous Sclerosis 1 Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphangioleiomyomatosis 1 Kidney Neoplasms 1 Hemangiosarcoma 1 Glioma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Temozolomide 109 Magnetic Resonance Spectroscopy 52 Bevacizumab 52 Radiotherapy 44 Irinotecan 27 Blood Specimen Collection 19 Surgical Procedures, Operative 16 Radiation 15 Aminolevulinic Acid 15 Carboplatin 13 fluorodopa F 18 12 Nivolumab 12 Radiotherapy, Intensity-Modulated 11 Carmustine 11 Radiosurgery 10 Magnetic Resonance Imaging 10 pembrolizumab 9 Topotecan 9 Specimen Handling 9 Everolimus 9 Erlotinib Hydrochloride 9 Biopsy 9 poly ICLC 8 Surveys and Questionnaires 8 Standard of Care 8 Etoposide 8 Drug Therapy 8 Lomustine 7 Filgrastim 7 Cyclophosphamide 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioma × Urination × Clear all

NCT06575452 2025-12-03

EPIGLIO

Institut du Cancer de Montpellier - Val d'Aurelle

Phase NA Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡